Expert Guidance to Optimize Adjuvant Therapy Decisions for HER2+ Early-Stage Breast Cancer: A CCO ClinicalImpact Program

Use CCO’s adjuvant breast cancer treatment decision tool to optimize clinical management of patients with EBC in your practice and review an expert-authored activity providing an overview of adjuvant therapy for HER2+ EBC and download the associated slideset. Gain expert perspectives on challenges in managing HER2+ EBC in 3 ClinicalThought commentaries.
Frankie Ann Holmes, MD, FACP
Joyce O'Shaughnessy, MD


Adjuvant treatment for HER2+ EBC is evolving with new agents and potentially practice-changing clinical trial data. Read my thoughts on how I am using these new findings in my clinical practice.

Joyce O'Shaughnessy, MD Released: April 12, 2018

Considering the Persephone and PerELIZA trial results, should we change our practices with HER2-targeted therapies for our patients with HER2-positive early breast cancer?

Frankie Ann Holmes, MD, FACP Released: June 22, 2018
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)

This activity is supported by an educational grant from

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?